Lp(a) in chronic kidney disease: state of the art and management perspectives.

Authors

Leonardo Spatola, Rosario Maccarrone, Matthias Zeiler, Antonio Granata

Published in

Journal of nephrology. Jul 28, 2026. Epub Jul 28, 2026.

Abstract

Patients with chronic kidney disease (CKD) exhibit a higher cardiovascular risk compared to the general population, due to CKD itself and its associated metabolic disorders, such as dyslipidemia. While statin-based management is the current gold standard therapy for dyslipidemia in mild to moderate CKD patients, it has a limited effect on lipoproteins, other than low density lipoproteins such as Lp(a). This limitation should be taken into consideration in cardiovascular risk stratification. Furthermore, statin therapy has not shown any beneficial effects in dialysis patients without prior cardiovascular disease, leading to uncertainty regarding the optimal dyslipidemia management in kidney failure (KF) patients. In this context, high serum Lp(a) levels (>105 nmol/L) should be acknowledged as a significant cardiovascular risk factor due to their pro-atherosclerotic and pro-calcific effects. However, selective Lp(a)-lowering therapies are still lacking in current clinical practice, although novel therapies are emerging in promising Phase III randomized trials. This narrative review summarizes the role of Lp(a) in CKD and discusses current state of the art and future therapeutic strategies.

PMID:
42517209
Bibliographic data and abstract were imported from PubMed on 28 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.